Circumferential Versus Ganglionated Plexi Ablation for Atrial Fibrillation (AF)

Atrial Fibrillation Clinical Trial

Official title:

Circumferential vs Ganglionated Plexi Ablation in Patients With Paroxysmal Atrial Fibrillation: A Randomized Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00671905
• Other study ID #: 1. 25/4/08
• Status: Completed
• Phase: N/A
• First received: April 30, 2008
• Last updated: April 10, 2013
• Start date: May 2008
• Est. completion date: August 2011

Study information

• Verified date: April 2013
• Source: Cardiovascular Research Society, Greece
• Contact: n/a
• Is FDA regulated: No
• Health authority: Greece: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The investigators have recently shown that anatomic ganglionated plexi (GP) ablation is inferior to circumferential pulmonary vein (PV) ablation for the treatment of paroxysmal AF. In this study, however, 26% of patients subjected to GP ablation alone without circumferential lesions were free of AF-recurrence up to one year after the ablation procedure. The investigators hypothesized that a combination of circumferential ablation with high-frequency-stimulation-identified GP ablation is superior to conventional circumferential ablation for the prevention of recurrences of paroxysmal atrial fibrillation (AF). The investigators are, therefore, conducting a randomized study comparing conventional circumferential ablation to a combination of circumferential ablation plus specific right and left atrial GP ablation in patients with drug-refractory paroxysmal AF.

Description:

Introduction:

In clinical studies, epicardial or endocardial partial ganglionated plexi (GP) ablation may prevent AF,1-4 and parasympathetic denervation has been proposed as a potential mechanism of circumferential or antral pulmonary vein (PV) ablation for the treatment of atrial fibrillation.5,6 However, there have also been reports of a temporary only 7 or even proarrhythmic effect of this approach by means of increased vulnerability of vagally-mediated AF,8,9 or ablation-related macro-reentrant left atrial tachycardias.10 Thus, the potential contribution of GP modification to clinical success of circumferential or antral pulmonary vein ablation that unavoidably affects adjacent GP is not known. Few publications exist on isolated GP ablation with variable results in terms of eliminating paroxysmal or persistent AF.11-13 We have recently shown that anatomically-oriented regional ablation at the areas of GP is superior to selective GP ablation, following identification of GP by high-frequency stimulation, conferring success rates comparable to these of pulmonary vein (PV) isolation procedures.13 We hypothesized that GP ablation guided by both HF stimulation and anatomical orientation is superior to PV isolation in patients with paroxysmal AF. We also aimed at comparing these two approaches with a combination of GP ablation and PV isolation. We are, therefore, conducting a randomized study comparing the three techniques in patients with drug-refractory paroxysmal AF.

Methods:

Patients with symptomatic, paroxysmal AF were randomized to three groups:

Group 1. Patients are subjected to conventional PV isolation through circumferential ablation 1-2 cm from the PV ostium.

Group 2. Patients are subjected to specific, HF stimulation-guided and anatomic ablation of the main right and left atrial GP.

Group 3. Patients are subjected to specific, HF stimulation-guided and anatomic ablation of the main right and left atrial GP followed by PV isolation.

Group 1. PV isolation. Circumferential ablation around the antra of the PV with the aid of electroanatomical mapping (Carto, Biosence-Webster) at a distance of approximately 1-2 cm from the ostia of the left and right PVs (46°C, 35W, 17 mL/min, Stockert, Biosense Webster), aimed at a voltage reduction by > 80% or a peak to peak bipolar electrogram <0.1 mV. End-point of both approaches is verification of PV isolation with demonstration of entry and exit block. The area encircled by circumferential ablation will be calculated using the software provided by the CARTO system.

Group 2. GP ablation. The anatomic areas of GP are identified in the right and left atrium. Anatomic locations of GP were considered around the PV: anterior right (ARGP), inferior right (IRGP), left superior (LSGP), and left inferior GP (LIGP). In addition the following GP were considered: The GP at the crux of the left atrium which is probably near or in continuation with the IRGP (2-3 cm below the lower edge of RIPV), expanding both toward the mitral annulus and inferior aspect of the LA posterior wall (cruxGP). This GP was also approached from the crux of the RA, behind the tendon of Tadaro/Eustachian ridge and the coronary sinus ostium. The GP at the septal-posterior aspect of the junction of the RA with the SVC (this GP may actually correspond to the 3rd fat pad located at the junction of SVC-RA-right PA-aorta).14-18 Following anatomic orientation, precise determination of the location of parasympathetic GP is accomplished by high-frequency stimulation.19 Patients are deeply sedated with diamorphine and diazepam without intubation, and high-frequency stimulation is delivered with a Grass stimulator at 1,200 bpm (20 Hz) with a pulse width of 10 ms at 20 V. A predominant parasympathetic response is defined as induction of AV block (> 2 sec) and hypotension or prolongation of the R-R interval by >50% during AF, following a 5 seconds application of high-frequency stimulation.19 Before applying high-frequency stimulation to inferior GP, extra care is taken to ensure that the catheter tip is not on the annulus to avoid induction of ventricular fibrillation. Verification of catheter position is accomplished by examination of recorded electrograms and anatomic location on both lateral views on CARTO. The sequence of GP ablation is: LS GP, LI GP, ARGP GP, IRGP, right anterior GP and the crux GP situated in the RA. After each ablation lesion (46°C, 35W for 60 seconds, 17 mL/min), parasympathetic response is reassessed by high-frequency stimulation. End-point for radiofrequency delivery is abolition of parasympathetic response. Following specific GP ablation, anatomical ablation is performed as previously described, in a way that the designated anatomic areas of GP are ablated.

Group 3. GP ablation and PV isolation. Following specific and anatomic GP ablation as previously described, PV isolation is accomplished either by circumferential or antral ablation.

At the end of the ablation procedure in both groups, AF or atrial flutter induction is attempted by isoproterenol infusion and high left atrial pacing. Induction of atrial fibrillation is registered but does not necessitate additional ablation. Induction of right, isthmus-dependent atrial flutter is dealt with cavotricuspid isthmus ablation. Left atrial flutters will be studied by means of entrainment from the mitral isthmus and the adjacent posterior wall. Since a considerable percentage of these arrhythmias disappear with time,20 they will be ablated only if sustained (> 3 minutes) and associated with 1:1 ventricular response.

Follow-up. Patients will be prospectively assessed for recurrence of AF or other atrial arrhythmia. As part of our routine AF ablation protocol, all patients are receiving beta blockers, whereas all patients are kept on amiodarone and warfarin for 3 months post-ablation. Patients will be subjected to monthly clinical assessment and ambulatory electrocardiographic monitoring for 2 years. All patients are instructed to maintain personal records with descriptions of every episode of symptomatic palpitations and, in case of persistent arrhythmia episodes, to obtain trans-telephonic or electrocardiographic documentation of the underlying rhythm. Patients will be encouraged to use trans-telephonic monitoring even when their symptoms are not typical for recurrent AF. A successful outcome over the follow-up period is defined as the lack of electrocardiographically recorded AF, and no AF or other atrial arrhythmia on Holter, and subjective symptomatic improvement after a 3-month blanking period.

Heart rate variability will be measured at 6, 12, 18 and 24 months after ablation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: August 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• paroxysmal AF

• age < 75 years

• left atrial size < 5 cm

Exclusion Criteria:

• malignancies

• LVEF < 35%

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Procedure:
• GP ablation
HF stimulation-guided and anatomic ablation of the main right and left atrial GP
• PV isolation
Circumferential PV isolation

Locations

Country	Name	City	State
Greece	Athens Euroclinic	Athens
Russian Federation	State Research Institute of Circulation Pathology	Novosibirsk

Sponsors (1)

Lead Sponsor	Collaborator
Cardiovascular Research Society, Greece

Countries where clinical trial is conducted

Greece,  Russian Federation, 

References & Publications (11)

Cummings JE, Gill I, Akhrass R, Dery M, Biblo LA, Quan KJ. Preservation of the anterior fat pad paradoxically decreases the incidence of postoperative atrial fibrillation in humans. J Am Coll Cardiol. 2004 Mar 17;43(6):994-1000. — View Citation

Hirose M, Leatmanoratn Z, Laurita KR, Carlson MD. Partial vagal denervation increases vulnerability to vagally induced atrial fibrillation. J Cardiovasc Electrophysiol. 2002 Dec;13(12):1272-9. — View Citation

Katritsis D, Giazitzoglou E, Sougiannis D, Goumas N, Paxinos G, Camm AJ. Anatomic approach for ganglionic plexi ablation in patients with paroxysmal atrial fibrillation. Am J Cardiol. 2008 Aug 1;102(3):330-4. doi: 10.1016/j.amjcard.2008.03.062. Epub 2008 May 22. — View Citation

Lemola K, Chartier D, Yeh YH, Dubuc M, Cartier R, Armour A, Ting M, Sakabe M, Shiroshita-Takeshita A, Comtois P, Nattel S. Pulmonary vein region ablation in experimental vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia. Circulation. 2008 Jan 29;117(4):470-7. doi: 10.1161/CIRCULATIONAHA.107.737023. Epub 2008 Jan 14. — View Citation

McClelland JH, Duke D, Reddy R. Preliminary results of a limited thoracotomy: new approach to treat atrial fibrillation. J Cardiovasc Electrophysiol. 2007 Dec;18(12):1289-95. Epub 2007 Oct 5. — View Citation

Nakagawa H, Jackman WM, Scherlag BJ, Lazzara R. Pulmonary vein isolation during atrial fibrillation: insight into the mechanism of pulmonary vein firing. J Cardiovasc Electrophysiol. 2003 Mar;14(3):261-2. — View Citation

Oh S, Zhang Y, Bibevski S, Marrouche NF, Natale A, Mazgalev TN. Vagal denervation and atrial fibrillation inducibility: epicardial fat pad ablation does not have long-term effects. Heart Rhythm. 2006 Jun;3(6):701-8. Epub 2006 Mar 6. — View Citation

Pappone C, Santinelli V, Manguso F, Vicedomini G, Gugliotta F, Augello G, Mazzone P, Tortoriello V, Landoni G, Zangrillo A, Lang C, Tomita T, Mesas C, Mastella E, Alfieri O. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. 2004 Jan 27;109(3):327-34. Epub 2004 Jan 5. — View Citation

Pokushalov E, Turov A, Shugayev P, Artyomenko S, Romanov A, Shirokova N. Catheter ablation of left atrial ganglionated plexi for atrial fibrillation. Asian Cardiovasc Thorac Ann. 2008 Jun;16(3):194-201. — View Citation

Scanavacca M, Pisani CF, Hachul D, Lara S, Hardy C, Darrieux F, Trombetta I, Negrão CE, Sosa E. Selective atrial vagal denervation guided by evoked vagal reflex to treat patients with paroxysmal atrial fibrillation. Circulation. 2006 Aug 29;114(9):876-85. Epub 2006 Aug 21. — View Citation

Schauerte P, Scherlag BJ, Pitha J, Scherlag MA, Reynolds D, Lazzara R, Jackman WM. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation. 2000 Nov 28;102(22):2774-80. — View Citation

* Note: There are 11 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Freedom of AF or other atrial arrhythmia		2 years	Yes
Secondary	Quality of life		2 years	Yes